IDH mutations have been found in 75% of low grade gliomas and secondary glioblastoma multiforme and approximately 20% of acute myeloid leukemia (Parsons et al., 2008; Mardis et al., 2009; Yan et al., 2009). Here, IDH1 is linked to central nervous system cancer.